Meda is a leading international pharma company with a broad product portfolio
Mylan’s acquisition of Meda was completed on August 5, 2016. Learn more.
Main switch board out of order
We are experiencing problems with our main switchboard so no calls are being transferred.
For urgent medical matters please contact us by phone: 072-734 46 62.
Apologies for this and we hope to have it solved shortly.
Meda has a well-diversified product portfolio, a global presence, and is represented within all areas of pharmaceuticals: Specialty Products, Cx, and OTC
CB12 is a powerful, unique and patented mouth rinse that ensures not only first class breath, but also provides a daily shot of confidence. Every day and all day CB12 provides 12 hours of protection.
EndWarts is an effective treatment for self-removal of warts on hands, feet and the body.
Dymista is a new nasal spray for the treatment of allergic rhinitis. Dymista is a novel formulation of Azelastine and fluticasone propionate.
Zyclara is an immune response modulator agent, Imiquimod 3,75%, for the treatment of large areas of actinic keratosis.
Elidel is a steroid free drug, Pimecrolimus, for the treatment of atopic dermatitis, which is a chronic recurring inflammatory skin disease.
This website is intended for people seeking information on Meda AB’s Global operations.
We also have national marketing sites. Links to these are under Meda Worldwide at the top of the page.